Table 1 Comparison of the baseline and treatment characteristics between the primary and postoperative GKRS group
Characteristic | Primary GKRS | Postoperative GKRS | P Value | Combined group |
|---|---|---|---|---|
No. of patients | 61 | 61 | NA | 122 |
Male, n (%) | 17 (27.9) | 17 (27.9) |  > 0.999 | 34 (27.9) |
Mean age, years | 46.8 ± 1.5 | 47.6 ± 1.3 | 0.688 | 47.2 ± 1.0 |
Non-skull base tumors, n (%) | 22 (36.1) | 21 (34.4) | 0.850 | 43 (35.2) |
Mean max diameter, mm | 34.8 ± 1.5 | 35.3 ± 1.5 | 0.819 | 35.0 ± 1.1 |
Tumor volume, median, (IQR), ml | 13.1 (5.8–18.8) | 12.5 (5.7–21.1) | 0.860 | 12.8 (5.7–21.0) |
Preexisting PTE, n, (%) | 6 (9.8) | 5 (8.2) | 0.752 | 11 (9.0) |
FU duration, median, (IQR), months | 73.8 (42.0–92.5) | 68.5 (37.0–112.6) | 0.961 | 72.7 (37.5–103.6) |
Symptomatic tumors, n, (%) | 31 (50.8) | 43 (70.5) | 0.026※ | 74 (60.7) |
CN dysfunction | 24 | 24 | NA | 48 |
I | 0 | 1 | NA | 1 |
II | 6 | 16 | NA | 22 |
III/IV/VI | 5 | 5 | NA | 10 |
V | 11 | 2 | NA | 13 |
VII | 4 | 1 | NA | 5 |
VIII | 6 | 3 | NA | 9 |
IX | 1 | 1 | NA | 2 |
X | 1 | 1 | NA | 2 |
Headache | 6 | 16 | NA | 22 |
Seizures | 3 | 2 | NA | 5 |
Vomiting | 0 | 2 | NA | 2 |
Extremity numbness | 1 | 3 | NA | 4 |
Extremity weakness | 2 | 3 | NA | 5 |
Ataxia | 2 | 3 | NA | 5 |
Tumor location | NA | NA | NA | NA |
Foramen magnum | 0 | 1 | NA | 1 |
Frontobasal | 2 | 3 | NA | 5 |
Tentorium | 2 | 4 | NA | 6 |
Convexity | 2 | 5 | NA | 7 |
CPA | 9 | 11 | NA | 20 |
Falx/parasagittal | 19 | 15 | NA | 34 |
Intraventricular | 1 | 1 | NA | 2 |
Orbital | 1 | 3 | NA | 4 |
Parasellar/cavernous sinus | 12 | 4 | NA | 16 |
Petroclival | 5 | 1 | NA | 6 |
Sphenoidal | 7 | 8 | NA | 15 |
Suprasellar | 1 | 5 | NA | 6 |
Margin dose, median, (IQR), Gy | 13.0 (12.0–13.0) | 13.0 (12.0–14.0) | 0.522 | 13.0 (12.0–13.5) |
Maximum dose, median, (IQR), Gy | 32.5 (30.0–34.2) | 33.0 (30.0–35.0) | 0.369 | 32.5 (30.0–35.0) |
Prescription isodose, median, (IQR), % | 40 (38–40) | 40 (35–43) | 0.576 | 40.0 (36.3–40.8) |